<DOC>
	<DOC>NCT00953732</DOC>
	<brief_summary>This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.</brief_summary>
	<brief_title>A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies</brief_title>
	<detailed_description>A 12 month long-term follow-up study of patients who have achieved complete clearance of AK lesions at the Day 57 in the Phase 3 studies PEP005-016 or PEP005-025.</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Patient must have achieved complete clearance of AK lesions (lesion count = 0) at Day 57 in one of the following Peplin AK clinical studies: PEP005016 or PEP005025 Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any studyrelated procedures Concurrent participation in another research study which would involve the selected treatment area (except for any poststudy followup visits for previous Peplin AK study) Early termination from study PEP005016 or PEP005025</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>